Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator (ICD) (SHIELD-2)

Inclusion Criteria:

- Have an ICD implanted and a history of ventricular tachycardia, ventricular
fibrillation, or an appropriate ICD therapy.

- Have a left ventricular ejection fraction <= 0.40

Exclusion Criteria:

- Have New York Heart Association (NYHA) Class IV Congestive Heart Failure (CHF) or
have decompensated CHF at the time of randomization;

- Have unstable angina pectoris or a myocardial infarction within 30 days of
randomization;

- Have a history of Torsade de Pointes or heart transplantation

- Have chronic atrial fibrillation or atrial fibrillation/flutter, that is not
adequately rate controlled in the judgment of the Investigator, at screening;

- Are currently taking systemic Class I or other Class III antiarrhythmic drugs

- Are currently taking systemic drugs that prolong the QT interval

- If female, are currently pregnant or breast feeding, or plan to become pregnant
during the course of the study